Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The VSports app下载. gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

Multicenter Study
. 2022 Apr 29;11(4):343-355.
doi: 10.1093/stcltm/szac003.

V体育2025版 - Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience

María Del Mar Macías-Sánchez  1   2 , Cynthia Morata-Tarifa  1 , Natividad Cuende  3 , Ana Cardesa-Gil  1 , María Ángeles Cuesta-Casas  4 , María Jesús Pascual-Cascon  4 , Antonia Pascual  4 , Carmen Martín-Calvo  5 , Manuel Jurado  6 , José Antonio Perez-Simón  7   8 , Ildefonso Espigado  7   8   9   10 , Sebastián Garzón López  11 , Gloria Carmona Sánchez  1 , Rosario Mata-Alcázar-Caballero  1 , Rosario Sánchez-Pernaute  1
Affiliations
Multicenter Study

Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience

María Del Mar Macías-Sánchez (VSports在线直播) et al. Stem Cells Transl Med. .

Abstract

Graft versus host disease (GVHD) is a severe complication after allogenic hematopoietic cell transplantation (HSCT). Several clinical trials have reported the use of mesenchymal stromal cells (MSCs) for the treatment of GVHD. In March 2008, the Andalusian Health Care System launched a compassionate use program to treat steroid-resistant GVHD with MSC. Clinical-grade MSC were obtained under GMP conditions. MSC therapy was administered intravenously in four separate doses of 1 × 106 cells/kg. Sixty-two patients, 45 males (7 children) and 17 females (2 children), received the treatment. Patients had a median age of 39 years (range: 7-66) at the time of the allogenic HSCT. The overall response was achieved in 58. 7% of patients with acute (a)GVHD. Two years' survival for aGVHD responders was 51. 85%. The overall response for patients with chronic (c)GVHD was 65. 50% and the 2-year survival rate for responders was 70%. Age at the time of HSCT was the only predictor found to be inversely correlated with survival in aGVHD. Regarding safety, four adverse events were reported, all recovered without sequelae VSports手机版. Thus, analysis of this compassionate use experience shows MSC to be an effective and safe therapeutic option for treating refractory GVHD, resulting in a significant proportion of patients responding to the therapy. .

Keywords: allogenic hematopoietic stem cell transplantation; cell therapy; graft versus host disease; mesenchymal stromal cells V体育安卓版. .

PubMed Disclaimer

Figures (VSports手机版)

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
Median number of doses of MSC was 3 (range 1–12), with the majority receiving four doses.
Figure 2.
Figure 2.
Sankey diagram of overall response and survival by sex and severity over time; the first column represents disease severity; the second column represents treatment response and the third column represents the status at last follow-up; the width of each bar represents their relative frequency within the cohort. (A) aGVHD patients with grades II, III, and IV. (B) cGVHD patients with grades, mild, moderate and severe (NIH severity scoring), and sex.
Figure 3.
Figure 3.
Response and Kaplan–Meier survival analysis. (A) Overall survival estimates for aGVHD patients, for responders (solid purple line), and for non-responders (solid blue line). (B) OS estimates for cGVHD patients, for responders (solid purple line), and for non-responders (solid blue line) (C) aGVHD and cGVHD response for adults, children, and overall.
See this image and copyright information in PMC

References

    1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-1826. 10.1056/NEJMra052638 - DOI - PubMed
    1. Ferrara JL, Levine JE, Reddy P, et al. . Graft-versus-host disease. Lancet. 2009;373(9674):1550-1561. 10.1016/S0140-6736(09)60237-3 - DOI - PMC - PubMed
    1. MacMillan ML, Weisdorf DJ, Wagner JE, et al. . Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8(7):387-394. 10.1053/bbmt.2002.v8.pm12171485 - "V体育ios版" DOI - PubMed
    1. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109(10):4119-4126. 10.1182/blood-2006-12-041889 - DOI - PMC - PubMed
    1. Van Lint MT, Milone G, Leotta S, et al. . Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006;107(10):4177-4181. - PubMed

"VSports最新版本" Publication types

MeSH terms

Substances